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A  recent  paper  by  Powers  et  al,  published  on  JAMIA,  notes  how  “after  Meaningful  Use  (MU)
objectives  in  2010  made  e­prescribing  a  requirement,  the  Centers  for  Medicare  and  Medicaid
Services (CMS) began requiring that source of the original prescription (handwritten, e­prescribed,
etc.) be reported on prescription drug events (PDEs) submitted to CMS”. The availability of these
data made  possible  researching  databases  of  patients  outcomes,  in  relation  to  the  ‘materiality’
(digital or otherwise) of the prescription.
Christopher Powers, Meghan Hufstader Gabriel, William Encinosa, Farzad Mostashari, Julie Bynum (2015)
Meaningful use stage 2 e-prescribing threshold and adverse drug events in the Medicare Part D population
with diabetes, Journal of the American Medical Informatics Association Sep 2015, 22 (5) 1094-1098;
http://jamia.oxfordjournals.org/content/22/5/1094
PS: we mentioned some of the challenges of studying the effects of primary care prescribing on Adverse Drug
Events in one of our papers: “Medication errors in repeat prescribing in primary care may be more difficult to
detect and study than prescribing errors in secondary care – for example, because (1) adverse events are only
detected when patients end up in hospital instead of returning to the practice (and the practice misses the
feedback on prescribing actions) and (2) the ‘errors’ may be connected with the continuation of the
prescription, rather than with specific issues of a prescription, requiring a more longitudinal assessment
approach”.
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